We use this note to address some concerns weighing on investor sentiment post the AGM update. We conclude these are overplayed and detract from the excellent work done by management to position CVS for sustained value accretion. The 15% de-rating is overdone on fundamental analysis and relative to major sector deals. Overall, we see the current share price weakness as a rare buying opportunity.